Form 4: Ligand Pharmaceuticals Director Trades LGND

Stephen L. Sabba, a Director at Ligand Pharmaceuticals Inc., reported transactions involving common stock and stock options on June 16, 2026.

Summary

• Director Stephen L. Sabba of Ligand Pharmaceuticals Inc. (LGND) engaged in stock transactions on June 16, 2026.
• Sabba acquired 2,145 shares of common stock at a price of $66.13 per share.
• Following this acquisition, Sabba beneficially owns 35,774 shares of common stock directly.
• Additionally, Sabba disposed of 2,145 shares of common stock at a price of $254 per share.
• After the disposition, Sabba beneficially owns 33,629 shares of common stock directly.
• The filing also notes a non-qualified stock option with an exercise price of $66.13, related to 2,145 shares, with a grant date of May 25, 2017, and vesting on the first anniversary or upon specific events like change in control or disability.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a mix of stock acquisition and disposition by a director, which is typical insider activity and does not inherently signal a strong positive or negative outlook for the company.

Positives

• Director acquired shares at a lower price point ($66.13), potentially indicating a belief in the stock's value at that level.
• The filing details a significant number of shares (33,629) still held directly by the director after the reported transactions.

Negatives

• Director sold a substantial number of shares (2,145) at a significantly higher price ($254) than the acquisition price, suggesting a realization of profit.

Risks

• The filing mentions that stock options vest immediately upon a change in control or hostile takeover, indicating a potential risk or trigger event for such options.
• Options also vest upon death or permanent disability of the grantee if still serving, highlighting personal risk factors.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The grant of 836 restricted shares was approved by the Board of Directors at the 2026 Meeting.
• The grant of 2,456 shares (adjusted to 2,145 shares with an exercise price of $66.13) was approved by the Board of Directors at the 2017 Meeting.
• The stock option grant vested in full on the first anniversary or immediately upon a change in control, hostile takeover, death, or permanent disability of the grantee.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the pharmaceutical and biotechnology sector, providing transparency on executive and director trading activities.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions provide insight into a director's confidence in the stock at different price points. The sale at a higher price may be interpreted as profit-taking, while the acquisition at a lower price could signal a belief in future appreciation.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Stock Options, Common Stock, Director Transactions, SEC Filing, Beneficial Ownership